Cagrilintide1kits (10Vials)

Cagrilintide – Detailed Introduction & Benefits Basic Introduction Cagrilintide (also known as AM833 ) is a long‑acting, acylated synthetic amylin analogue developed by Novo Nordisk for the treatment of obesity and type 2 diabetes (T2D) . Class : Amylin receptor agonist (dual amylin/calcitonin receptor agonist). Structure : Modified from pramlintide (an older amylin drug) with 3 amino acid substitutions and N‑terminal lipidation, extending its half‑life to ~1 week . Administration : Once‑weekly subcutaneous injection Novo Nordisk . Development status : Phase 3 trials completed; under regulatory review (2026). Often combined with semaglutide as CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) Novo Nordisk . Mechanism of Action Mimics amylin : Amylin is a hormone co‑secreted with insulin by pancreatic beta‑cells; it regulates appetite, gastric emptying, and glucose homeostasis. Slows gastric emptying : Delays stomach emptying, prolonging satiety and reducing meal size. Suppresses appetite (dual pathways) : Homeostatic : Acts on the hypothalamus to reduce hunger signals. Hedonic : Reduces cravings for high‑calorie, palatable foods (e.g., sugar, fat). Inhibits glucagon : Suppresses post‑meal glucagon secretion, lowering blood glucose. Enhances energy expenditure : Modulates fat metabolism and increases calorie burn in preclinical models. Main Benefits 1. Significant Weight Loss (Monotherapy & Combined) Monotherapy (2.4 mg/week) : Achieves 9–11% total body weight loss in 6–12 months. CagriSema (2.4/2.4 mg) : Delivers 17–22% weight loss (60% of patients lose ≥20%), superior to semaglutide 2.4 mg alone . Targets visceral fat : Reduces belly and liver fat more effectively than GLP‑1 monotherapy. 2. potent Glycemic Control (Type 2 Diabetes) HbA1c reduction : ~1.5–2.0% (monotherapy) ; ~2.2% (CagriSema) . Fasting glucose : Reduces by ~3.3 mmol/L in T2D patients. Post‑meal spikes : Blunts postprandial glucose elevations via slowed gastric emptying and glucagon inhibition. 3. Synergistic Metabolic Effects (CagriSema) Combines amylin (cagrilintide) and GLP‑1 (semaglutide) pathways for complementary appetite and glucose regulation. Greater improvements in insulin sensitivity and beta‑cell function than either drug alone. 4. Cardiometabolic Protection Blood pressure : Reduces systolic BP by ~5–8 mmHg . Lipids : Lowers triglycerides and LDL (“bad” cholesterol); raises HDL (“good” cholesterol). Liver health : Improves non‑alcoholic fatty liver disease (NAFLD) markers by reducing hepatic fat accumulation. 5. Reduced Cravings & Emotional Eating Specifically curbs cravings for sugary, high‑fat, and processed foods . Reduces emotional eating and binge‑eating episodes, supporting sustainable weight management. 6. Safety & Tolerability Mild‑to‑moderate side effects : Nausea, vomiting, diarrhea, constipation (typically transient, resolving within 4–8 weeks) Novo Nordisk . Low hypoglycemia risk : Rarely causes low blood glucose when used alone; minimal risk with metformin/semaglutide. Key Advantages Over GLP‑1 Monotherapy Dual appetite control : Targets both hunger and food cravings (GLP‑1 mainly reduces hunger). Greater weight loss : CagriSema outperforms semaglutide 2.4 mg (the current gold standard). Better for “emotional eaters” : More effective for those with cravings or binge‑eating tendencies. Applications Chronic weight management (overweight/obesity, BMI ≥27) Novo Nordisk . Type 2 diabetes (with/without obesity) Novo Nordisk . Metabolic syndrome (high BP, high glucose, high triglycerides). NAFLD/non‑alcoholic steatohepatitis (NASH) (adjunctive therapy). Important Note Cagrilintide/CagriSema is not yet FDA‑approved (as of 2026); available only via clinical trials or compassionate use programs Novo Nordisk .